Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS OncoTherapy, Panasonic Healthcare to Codevelop Immune Monitoring System to Evaluate Effects of Cancer Vaccines
July 26, 2013
-
REGULATORY MHLW Might Submit Bill on Online OTC Sales to Extraordinary Diet Session: PFSB Head
July 25, 2013
-
BUSINESS Otsuka to Develop Sensor-Embedded Abilify to Improve Drug Compliance
July 24, 2013
-
REGULATORY Pilot Program for Japan-Version “Compassionate Use” System to Begin at National Cancer Center
July 23, 2013
-
REGULATORY 1st Committee to Discuss Approval of New Products Including Janssen’s Extended Release Schizophrenia Treatment
July 23, 2013
-
REGULATORY MHLW Mulls “Ultra-Orphan” Drug System; Designation Might Become Possible with Pre-Clinical, Healthy Subject Data
July 22, 2013
-
REGULATORY US Aims for Lifting of Ban on Mixed Care: Prof. Murakami of Yamagata University
July 22, 2013
-
ORGANIZATION FPMAJ Settles on Industry View for TPP, Demands Intellectual Property Protection on Par with Japanese Rules
July 19, 2013
-
REGULATORY South Korean MOHW Officials Announce Roadmap for South Korea to Become No. 7 Worldwide in New Drug Development by 2020
July 19, 2013
-
BUSINESS Pfizer Paid 23.9 Billion Yen to Physicians, Medical Institutions in FY2012; 1st Disclosure under JPMA Guidelines
July 18, 2013
-
ACADEMIA University’s Seriousness to Unravel Diovan Saga Called into Question
July 17, 2013
-
REGULATORY 2nd Committee on Drugs to Discuss Approval for Asthma Treatment Flutiform on July 26
July 17, 2013
-
REGULATORY MHLW, US FDA to Exchange Information with a View to Standardizing Review Guidelines for Regenerative Medicines
July 17, 2013
-
REGULATORY Health Ministry to Set Up Committee on Diovan Studies, Compile Preventive Measures for Clinical Data Manipulation
July 16, 2013
-
REGULATORY MHLW Presses Kyoto Prefectural University of Medicine to Carry on Diovan Probe
July 16, 2013
-
ACADEMIA “Data Manipulated” in KYOTO Heart Study: Univ. Probe
July 12, 2013
-
ORGANIZATION JPWA Sets Up New Committee on Consumption Tax, NHI Drug Pricing Issues
July 12, 2013
-
BUSINESS Drug Makers to Disclose Payment Information This Summer Based on Transparency Guidelines
July 11, 2013
-
BUSINESS Blood Derivative Titan CSL Set to Beef Up Japan Biz with New Products
July 10, 2013
-
REGULATORY TPP Member States to Brief Japan on Drug Pricing, Intellectual Property on July 25
July 9, 2013
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…